Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.

Highlights from the article: Patients with relapsed or refractory AL amyloidosis have limited treatment options. Out of 23 patients with evaluable organ response, 5 of 13 patients had a renal response and 1 of 14 patients had cardiac response. In patients with refractory and/or relapsed AL amyloidosis with limited therapeutic options Ben/Dex is a viable treatment option that produced a substantial hematologic response and increased survival.